



## **Laureate Pharma and Selexis Announce Collaboration**

- Collaboration Will Provide an Efficient Approach for Production of Clinical Material -

**Princeton, NJ; Geneva, Switzerland, Boston, MA, January 5, 2010** – Laureate Pharma, Inc. a US based biopharmaceutical contract manufacturing organization and Selexis SA, a Swiss based contract developer of high performance production cell lines, jointly announced today their continued collaboration via a joint-marketing relationship. This expanded relationship provides streamlined access to a set of highly complementary contract services.

Such relationship offers the opportunity to generate highly productive, stable mammalian cells producing gram quantities of recombinant protein materials in as little as eight weeks, post transfection. In parallel, cGMP compliant manufacturing processes can be developed for a streamlined approach for the production of clinical-grade material.

“We are pleased to be working with Selexis and their highly advanced approach to developing high performance production cell lines” said Dr. Robert Broeze, President & CEO of Laureate Pharma. “Combining the Selexis approach to cell line development with our strong track-record of cGMP manufacturing provides a very compelling value proposition for clients looking to outsource biopharmaceutical manufacturing”

“Including Laureate in our network of manufacturing partners is of great benefit to our clients seeking a US based manufacturer with a long history of successful cGMP compliant manufacturing”, said Dr. Igor Fisch, President and CEO of Selexis.

“Laureate is a leader in this area and we are very pleased to be in association with this strong organization.”

### **About Selexis**

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in



the time, effort and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells. Application of the *Selexis Genetic Elements*<sup>™</sup> using the *SURE Cell Line Development*<sup>™</sup> process has enabled the rapid development of high-performance cell lines for a number of pharmaceutically important programs.

### **About Laureate Pharma, Inc.**

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, NJ. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products.

### **For more information:**

Laureate Pharma, Inc.

Dan Leone, Vice President, Business Development

T 609-919-3300

E-mail: [info@laureatepharma.com](mailto:info@laureatepharma.com) or visit [www.laureatepharma.com](http://www.laureatepharma.com)

Selexis SA

Andrew Sandford, Vice President, Business Development

T +41 (0) 22 308 93 60

E-mail: [info@selexis.com](mailto:info@selexis.com), or visit [www.selexis.com](http://www.selexis.com)